Design, Synthesis and Biological Evaluation of Pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione Derivatives as Novel Neuroprotective Agents

被引:0
作者
Jishun Quan
Dongping Zhang
Zhuo Zhang
Jian Wang
Chao Ma
Maosheng Cheng
机构
[1] Shenyang Pharmaceutical University,Key Laboratory of Structure
来源
Chemical Research in Chinese Universities | 2021年 / 37卷
关键词
Neuroprotective activity; Ca; influx; Western blotting; NR2B-NMDA receptor; Molecular docking;
D O I
暂无
中图分类号
学科分类号
摘要
A series of pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione derivatives was designed and synthesized, and their neuroprotective activity against SH-SY5Y cell injury induced by N-methyl-D-aspartic acid(NMDA) was evaluated. All the compounds showed significant neuroprotective effects, especially B16, which showed excellent performance and better activity than the positive control ifenprodil(B16: 56.2%±0.6%; ifenprodil: 41.0%±2.7%). Further investigation indicated that B16 could attenuate the Ca2+ influx induced by NMDA in SH-SY5Y cells and Western blotting also showed that B16 could attenuate the NR2B upregulation in SH-SY5Y cells induced by NMDA. The molecular docking results showed that compound B16 fitted in the binding pocket of NR2B-NMDAR well and could interact with binding sites of compounds 1 and 2 simultaneously. The ADME/Tox prediction results suggested that compound B16 had good blood-brain barrier(BBB) permeability and the zero alert of Pan Assay Interference Structures(PAINS) indicated that B16 could not elicit false-positive activities. These results strongly suggest that B16 is a promising and effective candidate neuroprotective compound, and that NR2B-NMDAR is a potential target of B16.
引用
收藏
页码:647 / 654
页数:7
相关论文
共 164 条
  • [1] Buemi M R(2016)undefined Bioorg. Med. Chem. 24 1513-undefined
  • [2] De Luca L(2016)undefined Bioorg. Med. Chem. Lett. 26 889-undefined
  • [3] Ferro S(2011)undefined J. Med. Chem. 54 8702-undefined
  • [4] Russo E(1998)undefined Drug News Perspect 11 523-undefined
  • [5] De Sarro G(2010)undefined Bioorg. Med. Chem. 18 8005-undefined
  • [6] Gitto R(2018)undefined Neuropharmacology 142 41-undefined
  • [7] Dey S(1998)undefined Br. J. Pharmacol. 125 1258-undefined
  • [8] Schepmann D(2017)undefined Consult Pharm. 32 511-undefined
  • [9] Wunsch B(2018)undefined Scand. J. Pain. 18 687-undefined
  • [10] Gitto R(2010)undefined Neuron 65 178-undefined